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Abstract
Polycystic Ovary Syndrome (PCOS) is known to be characterized by metabolic disorder in which hyperinsulinemia and
peripheral insulin resistance are central features. Given the physiological overlap between PCOS and type-2 diabetes
(T2DM), and calpain 10 gene (CAPN10) being a strong candidate for T2DM, a number of studies have analyzed CAPN10 SNPs
among PCOS women yielding contradictory results. Our study is first of its kind to investigate the association pattern of
CAPN10 polymorphisms (UCSNP-44, 43, 56, 19 and 63) with PCOS among Indian women. 250 PCOS cases and 299 controls
from Southern India were recruited for this study. Allele and genotype frequencies of the SNPs were determined and
compared between the cases and controls. Results show significant association of UCSNP-44 genotype CC with PCOS
(p=0.007) with highly significant odds ratio when compared to TC (OR=2.51, p=0.003, 95% CI=1.37–4.61) as well as TT
(OR=1.94, p=0.016, 95% CI=1.13–3.34). While the haplotype carrying the SNP-44 and SNP-19 variants (21121) exhibited a 2
fold increase in the risk for PCOS (OR=2.37, p=0.03), the haplotype containing SNP-56 and SNP-19 variants (11221) seems
to have a protective role against PCOS (OR=0.20, p=0.004). Our results support the earlier evidence for a possible role of
UCSNP-44 of the CAPN10 gene in the manifestation of PCOS.
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Introduction
Polycystic ovary syndrome (PCOS) is the most common
reproductive endocrinopathy of women in their childbearing years
and is responsible for an estimated 70% of cases of anovulatory
infertility. In addition to the clinical features of hyperandrogenism
and chronic anovulation, many women are insulin resistant and at
increased risk for type-2 diabetes mellitus (T2DM) [1]. Previous
studies have established that the prevalence of impaired glucose
tolerance and T2DM among women with PCOS has been
constantly increasing with consistency across populations of varied
ethnicand racialbackgrounds[1,2,3].Geneticstudieshaverevealed
that PCOS and T2DM could share genetic susceptibility factors
associated with both the pathologies. Using this hypothesis, several
studies have suggested that genes related to T2DM may also play a
role in PCOS pathogenesis [4–11]. Calpain 10 (CAPN10) is a
candidate gene for T2DM, positionally cloned on 2q chromosome
[12], and found to be associated with T2DM in several populations
[12–14]. Most of the subsequent studies found association of
CAPN10 gene with PCOS phenotypes as well [7–11,15]. While
Ehrmann et al. [7], Gonzalez et al. [8,9] and Vollmert et al. [15]
reported association of CAPN10 with PCOS and quantitative
measures such as fasting insulin, blood glucose levels related to
T2DM, Escobar-Morreale et al. [10] reported an association of
CAPN10 polymorphism with hirsutism. In contrast, Haddad et al.
[11] reported no association of CAPN10 with PCOS.
The nature of association of CAPN10 with PCOS has not been
hitherto studied among the Asian populations in general and
particularly among the Indians albeit its association is fairly
established with T2DM among the Asians, including the Indian
populations [16–18]. We present here the results of our pioneering
effort in investigating the association of five CAPN10 SNPs
(UCSNP-44, UCSNP-43, UCSNP-56, UCSNP-19 and UCSNP-
63) with polycystic ovary syndrome among South Indian women.
Results
Clinical characteristics of the study population
For majority of the PCOS cases, the data on clinical and/or
biochemical parameters were obtained and the characteristics that
are relevant to the metabolic component of PCOS are presented
in Table 1, according to the BMI categories. The total number of
cases ‘N’ denotes the number of cases for which the respective data
could be obtained. Over 90% of the PCOS cases were aged below
30 and only one woman aged above 35. The random blood sugar
(RBS) as well as fasting insulin (FI) levels of these cases were in the
normal range, hence, non-diabetic. Therefore, no further tests
related to diabetic profile were warranted. In the present study, the
recruitment was made only after confirmation of PCOS through
the Rotterdam criteria. Most of the patients approached the
collaborating clinicians with the problem of menstrual irregular-
ities, who were subsequently diagnosed as PCOS after confirma-
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Therefore, the data presented is not a mere presentation of the
prevalence of the diagnostic features, but the actual data of the
patients that were encountered in the clinical centers. All the cases
with ultrasound data had polycystic ovary morphology along with
the clinical presentation of irregular menstrual cycles. Nearly 79%
of the PCOS cases in the present study were reported to be
infertile and were under treatment. The remaining patients were
young unmarried women primarily approaching the clinician with
the symptom of irregular menses before being diagnosed as PCOS,
hence their infertility status could not be ascertained. Among the
other clinical features of PCOS, hirsutism and acanthosis nigricans
were significantly more frequent in the obese PCOS cases than the
lean PCOS cases (p,0.001). A significantly greater proportion of
obese cases had elevated cholesterol levels (.200 mg/dl) than the
lean PCOS cases (p=0.002). Unfortunately, the biochemical
parameters could not be obtained for the control group which
would have enabled a comparison between the cases and controls.
Genotype and allele frequencies of CAPN10 SNPs
The genotype and allele frequency distribution for the five SNPs
are presented in Table 2 and Table 3, respectively. We observed a
significantly higher frequency of homozygotes for the polymorphic
variant C at the UCSNP-44 locus (intron 3) among the PCOS
cases than the controls (17.4% vs 8% respectively, p=0.007). This
trend was also seen in the allele distribution pattern, wherein the
variant allele C was found in 27.8% of the PCOS cases as
compared to 22.4% of the controls. However, the statistical
significance for this allele was not retained after Bonferroni
correction for multiple testing. Logistic regression analysis of
PCOS status on the UCSNP-44 genotypes taking age and BMI as
covariates yielded significant odds ratio for the CC genotype when
Table 1. Clinical profile of the PCOS cases under study.
Phenotypic features All patients Lean PCOS (BMI,25) Obese PCOS (BMI$25)**
N% N % N%
PCO 124/124 100 30/30 100 43/43 100
Menstrual irregularities 210/210 100 56/56 100 104/104 100
Hirsutism* 175/230 76.1 41/54 75.9 96/101 95
Acne 47/230 20.4 13/54 24.1 23/101 22.7
Acanthosis nigricans* 110/220 50 19/54 35.2 68/101 67.3
Infertility 181/230 78.7 43/55 78.2 77/104 74
Elevated Cholesterol (.200 mg/dl)* 38/150 25.3 1/25 4 25/80 31.2
*significantly different between lean PCOS and obese PCOS cases (p#0.002).
**Given the lean body mass of Indian women (Asian Indian Phenotype), BMI$25 is generally considered as cut off distinguishing the lean women from overweight/
obese women albeit the WHO criteria specifies BMI.30 as obese.
doi:10.1371/journal.pone.0032192.t001
Table 2. Genotype frequency distribution of CAPN10 polymorphisms among PCOS cases and controls.
SNP ID UCSNP ID Gene location Genotype PCOS Cases (N=248) Controls (N=298) *a
2 (p-value)
rs2975760 44 Intron 3 TT 0.618 0.640 9.79 (0.007)
TC 0.207 0.271
CC 0.174 0.089
rs3792267 43 Intron 3 GG 0.828 0.824 2.93 (0.23)
GA 0.159 0.127
AA 0.012 0.031
rs2975762 56 Intron 4 GG 0.292 0.269 2.33 (0.31)
GA 0.483 0.447
AA 0.224 0.284
rs3842570 19 Intron 6 Del/Del
# 0.229 0.228 0.09 (0.96)
Del/Ins
# 0.459 0.449
Ins/Ins
# 0.310 0.322
rs5030952 63 39UTR CC 0.916 0.913 0.88 (0.65)
CT 0.076 0.070
TT 0.008 0.017
*Standard Pearson chi square value with degree of freedom=2.
#Del – Deletion.
Ins – Insertion.
doi:10.1371/journal.pone.0032192.t002
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ly) (Table 4) with a statistical power (1-b error probability) of 99%.
The case cohort was also analyzed in two groups, based on body
mass index (BMI), i.e. lean PCOS (BMI,25) and obese PCOS
(BMI$25) cases. The allele and genotype frequencies were
compared between these two groups as well as each of them with
controls (pooled). The control group was also categorized
according to BMI, and similar comparison was carried out
between the BMI matched case and control groups (lean cases vs
lean controls, and obese cases vs obese controls). This analysis did
not yield any significant observation (results not presented).
Using PyPop software, the observed genotype counts were
compared with those expected under Hardy–Weinberg propor-
tions (HWPs), and a x
2 test was carried out to check for the
significance of deviation from HWP for each SNP locus in PCOS
women and controls separately. All the loci, except UCSNP-44,
confirm to the Hardy-Weinberg equilibrium, in both the cases and
the controls. The departures from HWP, in case of UCSNP-44,
were observed to be due to increased proportion of the
homozygotes in both cases and controls.
Given that our sample consisted of sizeable cohort of Muslim
subjects, we repeated the genotype analysis for the Hindu caste
and Muslim subjects separately. But this categorization does not
seem to change genotype distribution profiles to any significant
degree (results not presented). Since the Muslim and Hindu cases
were predominantly drawn from the Osmania General Hospital
and Anu Test Tube Baby Centre, respectively, which represented
lower and higher socioeconomic strata, the results also do not
suggest any effect of socioeconomic status in the pattern of
manifestation of PCOS in relation to CAPN10 SNPs. Further, we
drew 50, 60 & 70% random subsets of case and control samples
and repeated the above analysis on each of the subsets to test for
internal consistency. Overall, the results suggest that the pattern of
distribution of the CAPN10 alleles and their association with
PCOS in each of the subsets is similar to the total sample (results
not presented) indicating internal consistency.
Linkage Disequilibrium among CAPN10 SNPs and
Haplotype analysis
Out of 250 PCOS cases and 299 controls, 223 cases and 266
controls could be used for the purpose of estimating linkage
disequilibrium (LD) for the five CAPN10 SNPs. As per the LD plot
(Figure 1), only two loci (UCSNP-44 and UCSNP-43) were in
perfect LD (D9=1). Except the loci combinations of SNP-
44:SNP56, SNP-44:SNP-19 and SNP-43:SNP-63, all the other
combinations exhibited strong LD (D9=0.82–0.92). Pairwise LD
estimates were also made for the case and control groups
separately (Table 5).While UCSNP-43 and UCSNP-44 were in
perfect LD (D9=1) in both the groups, UCSNP-63 depicted
different LD patterns among the cases and controls. While in cases
it was observed to be in perfect LD with UCSNP-56 and UCSNP-
19, among the controls, UCSNP-63 shows strong LD with both
UCSNP-43 and -44 (D9=1). Strong LD was also observed for
UCSNP-19:UCSNP-43, UCSNP-19:UCSNP-56 and UCSNP-
43:UCSNP56 in both case and control groups.
Haplotypes based on the five CAPN10 SNPs (UCSNP-44, -43, -
56, -19 and -63) were constructed and analyzed for possible
association with PCOS (Table 6). A total of nine haplotypes, with a
frequency of .1%, was obtained in the entire cohort of 489
individuals. Interestingly, we could infer both risk conferring and
protective haplotypes from their comparative distribution in the
case and control groups. The proportion of 21121 and 11221
haplotypes differed significantly between the case and control
groups. While 21121 haplotype was significantly more frequent
among the cases, the 11221 haplotype was overrepresented among
the controls. The logistic regression analysis using 11121 as
reference haplotype suggests significant odds for both 21121 and
11221 haplotypes (Table 7), albeit in different directions; while
21121 is risk conferring, 11221 is protective against PCOS. Two
other haplotypes (21221 and 11111) also exhibited marginal
association with the control group. However, after performing
Bonferroni correction for multiple testing, the association pattern
remained significant only for 11221 haplotype.
Table 3. Allele frequency distribution of CAPN10 polymorphisms among PCOS cases and controls.
SNP ID UCSNP ID Allele PCOS Cases (2 N=496) Controls (2 N=596) *a
2 (p-value)
rs2975760 44 T 0.722 0.775 4.08 (0.04)
C 0.278 0.224
rs3792267 43 G 0.908 0.905 0.02 (0.89)
A 0.092 0.094
rs2975762 56 G 0.534 0.493 1.72 (0.18)
A 0.466 0.507
rs3842570 19 Del 0.540 0.547 0.05 (0.83)
Ins 0.460 0.453
rs5030952 63 C 0.954 0.948 0.19 (0.65)
T 0.046 0.052
*Standard Pearson chi square value with degree of freedom=1.
doi:10.1371/journal.pone.0032192.t003
Table 4. Logistic regression analysis of UCSNP-44 for
association with PCOS, taking age and BMI as covariates.
SNP ID UCSNP
Genotypes
compared Odds ratio95% CI@ p-value
rs2975760 UCSNP-44 CC vs TT 1.94 1.13–3.34 0.016
CC vs CT 2.51 1.37–4.61 0.003
CC/CT vs TT 1.05 0.73–1.50 0.784
@CI – Confidence interval.
doi:10.1371/journal.pone.0032192.t004
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PCOS
Given the significant haplotype association results, we further
explored the role of these specific haplotypes in the manifestation
of certain clinical characteristics of PCOS. We compared different
haplotype combinations between two groups of patients divided on
the basis of presence/absence of a particular PCOS phenotypic
trait (i.e hirsutism, obesity, infertility, and hypercholesterolemia)
(Figure 2). While a greater proportion of the hirsutism trait was
observed in cases with 21111/21221 combination, all the other
traits i.e. obesity, infertility and elevated cholesterol levels
(.200 mg/dl) were found in greater frequency among cases with
11111/21221 combination. Although these comparisons provided
some pattern of association between the haplotype combinations
and phenotypic traits, the magnitude of differences between the
two groups of patients was not statistically significant.
Discussion
PCOS, as a syndrome, has multiple components- reproductive,
metabolic and cardiovascular- with long term health implications.
In addition to the clinical features of hyperandrogenism and
chronic anovulation, many PCOS women are insulin resistant and
are at high risk to develop type-2 diabetes. Clinical and laboratory
based studies in PCOS have variously pointed to abnormalities of
insulin receptor binding, or more plausibly, post receptor signaling
as well as to the evidence for a primary abnormality of insulin
secretion [19]. Therefore, numerous genes involved in insulin
action and secretion have been explored as candidate genes in the
PCOS pathology. The CAPN10 gene, encoding a ubiquitous
member of the calpain-like cysteine protease family, plays a role in
insulin secretion and action [20] and was positionally cloned
within the NIDDM1 region [12]. The presence of calpain-10
mRNA in pancreatic islets, muscle, and liver, the three most
important tissues that control blood glucose levels, suggests that
calpain-10 may regulate pathways that affect insulin secretion,
insulin action, and hepatic glucose production, each of which is
altered in patients with type 2 diabetes [20]. Variation in the
Figure 1. Linkage disequilibrium plot for CAPN10 polymor-
phisms in the entire cohort of PCOS cases and controls. D9
values are mentioned in the LD blocks.
doi:10.1371/journal.pone.0032192.g001
Table 5. Pairwise LD estimates in PCOS cases and controls. Data are D9 values.
LOCUS PAIR PCOS CASES (N=223) CONTROLS (N=266) TOTAL COHORT (N=489)
UCSNP19 : UCSNP43 0.91475 0.93013 0.92
UCSNP19 : UCSNP44 0.54032 0.55093 0.54
UCSNP19 : UCSNP56 0.90743 0.80621 0.85
UCSNP19 : UCSNP63 1 0.74352 0.82
UCSNP43 : UCSNP44 1 1 1
UCSNP43 : UCSNP56 0.91568 0.83889 0.86
UCSNP43 : UCSNP63 0.02091 1 0.00
UCSNP44 : UCSNP56 0.53209 0.71771 0.61
UCSNP44 : UCSNP63 0.8095 1 0.89
UCSNP56 : UCSNP63 1 0.797 0.87
doi:10.1371/journal.pone.0032192.t005
Table 6. CAPN10 haplotype frequency distribution among
PCOS cases and controls.
Haplotype
PCOS cases
(2 N=446)
Controls
(2 N=532) a
2* p-value
21211 0.211363 0.170812 2.66 0.103
21221 0.008581 0.026489 4.07 0.043
21121 0.062426 0.030489 5.97 0.014
11211 0.190294 0.199673 0.21 0.645
11212 0.041883 0.046397 0.14 0.705
11221 0.015426 0.061543 14.27 ,0.0001
11111 0.012502 0.032079 4.25 0.039
11121 0.353587 0.327145 0.73 0.392
12121 0.085226 0.081487 0.01 0.903
*Standard Pearson chi square value with degree of freedom=1.
doi:10.1371/journal.pone.0032192.t006
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2 diabetes mellitus (T2DM) susceptibility in a Mexican American
population [12]. Specific combinations of three intronic variants,
designated as ‘‘SNP- 43,’’ ‘‘SNP-19,’’ and ‘‘SNP-63,’’ that capture
most of the haplotype diversity at CAPN10 were associated with a
three-fold increased risk for T2DM in this population [12].
However, Evans et al. [13] reported that another variant, SNP-44
located in intron 3 and separated by 11 base-pairs from SNP-43,
was independently associated with T2DM in whites from the
United Kingdom. Apart from being a strong candidate for T2DM
[12,13], the CAPN10 gene has been widely evaluated in traits such
as PCOS and idiopathic hirsutism [7–11,15] due to the fact that
PCOS and type-2 diabetes share a number of etiologic factors.
Preliminary studies of CAPN10 gene in PCOS patients from the
United Kingdom provide the first evidence of CAPN10 involve-
ment in PCOS, suggesting a statistically significant association
between the UCSNP-44 allele and PCOS susceptibility (cited in
Gonzalez et al. [9]). Subsequent studies evaluating the role of
CAPN10 in PCOS have yielded contradictory results. Supporting
the CAPN10 gene involvement in PCOS, Gonzalez et al. [8,9]
showed that CAPN10 UCSNP-44 allele was associated with
PCOS in the Spanish population. Another study in the Spanish
population has suggested that CAPN10 UCSNP-43 allele
somehow influences the hirsutism score in hyperandrogenic
patients while UCSNP-45 could be associated with idiopathic
hirsutism [10]. While Ehrmann et al. [7] and Vollmert et al. [15]
have shown association of UCSNPs-19, -63 and UCSNPs-19, -56,
respectively, with PCOS phenotype, Haddad et al. [11] did not
find any association between CAPN10 SNPs and PCOS. The
significance of the association between the SNPs/haplotypes with
PCOS is underlined by the positive correlation of two adjacent
SNPs - UCSNP-43 and UCSNP-44 - specifically with hyperan-
drogenic features that are central to PCOS [9,10].
Some recent CAPN10 studies among Indian populations have
focused on T2DM, but not on PCOS [16–18]. While Cassell et al.
[16] and Adak et al. [17] reported that haplotypes containing SNP-
19 and SNP-63 alleles increase risk for T2DM, Bodhini et al. [18]
concluded that 2111 haplotype of SNPs –44, –43, –19, and –63
may be associated with type 2 diabetes mellitus, although none of
these SNPs may be individually associated with diabetes. In an
attempt to explore possible association of CAPN10 gene variants
with risk for PCOS, we carried out this study in a largest cohort of
South Indian women with PCOS hitherto examined for CAPN10
SNPs in a case-control setup. Even with a minimum effect size of
0.1, our sample size of 549 (250 cases+299 controls) is large
enough and far exceeds the estimated number of samples (,250
cases+controls) required to obtain a 90% statistical power.
Table 7. CAPN10 haplotype effect: Haplotypic OR by
comparison to the reference with its 95% CI.
Haplotype Odds Ratio* 95% CI p- value
21121 2.37 1.06–5.30 0.035
11221 0.20 0.06–0.59 0.004
*(in comparison to the reference haplotype 11121).
doi:10.1371/journal.pone.0032192.t007
Figure 2. Analysis of specific CAPN10 haplotypes with different clinical phenotypes of PCOS.
doi:10.1371/journal.pone.0032192.g002
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was based on the knowledge of their previous association with
PCOS as well as T2DM [7–18]. While UCSNP-43 alone has been
strongly associated with T2DM and insulin resistance, both
UCSNP-43 and -44 have been implicated in the transcriptional
regulation of the CAPN10 gene [12]. Of the five SNPs analyzed,
we found significant association of UCSNP-44 with PCOS at the
genotype as well as allele frequency level. The homozygous
genotype for the polymorphic allele of UCSNP-44 (CC) was
associated with 2–2.5 fold increase in risk for PCOS as compared
to the other genotypes. Given the internal consistency of our
findings and their concurrence to the earlier evidence [8,9], the
present study underscores the importance of UCSNP-44 of
CAPN10 in PCOS pathophysiology. The significance of this
association is further highlighted through the functional studies
suggesting that SNP-44 is located in an enhancer element and
might affect CAPN10 expression [12].
In our cohort, the haplotype 21121 (UCSNPs -44,-43,-56,-19
and -63) was found to be significantly associated with PCOS
(p=0.014) although this significance was not retained after
Bonferroni correction; this haplotype, comprising of the variant
alleles of UCSNP-44 and UCSNP-19, exhibited a two-fold
increased risk of PCOS (OR=2.37, p=0.03). We also obtained
significant association of haplotype 11221 (UCSNPs -44,-43,-56,-
19 and -63), comprising of UCSNP-56 and UCSNP-19 variant
alleles, with increased frequency among the controls, which was
significant even after Bonferroni correction (p,0.0001). We could
infer from the odds ratio (OR=0.20, p=0.004) that this haplotype
(11221) might have a significant protective role against PCOS.
However, analysed individually, neither of the variants for
UCSNP-56 and UCSNP-19 depicted any significant difference
in genotype or allele frequency distribution patterns. We find both
risk conferring and protective haplotypes in our cohort, with
UCSNP-19 variant allele being common to both of them. This
could probably be due to relatively large minor allele frequency of
UCSNP-19 (45%) in our cohort. This has reflected in 11121 being
the most frequent haplotype comprising only UCSNP-19 as the
variant allele among the PCOS cases and controls with a
frequency of 35% and 33% respectively. Our haplotype results
are partially concurrent to the observations of Bodhini et al. [17]
concerning the presence of UCSNP-44 allele in the risk conferring
haplotypes in another South Indian sample, suggesting UCSNP-44
as an important marker in the pathophysiology of PCOS and/or
T2DM particularly among South Indian populations. The
difference in the risk conferring haplotypes between the two studies
lies at the UCSNP-19 locus (21121 versus 21-11), even though the
variant allele frequency for this locus is comparable between the two
samples(45% in our study; 56% in the earlier study). Further,
compared to Bodhini et al. [17] UCSNP-56 locus is additionally
studied by us. The variant allele frequencies of all the CAPN10
SNPs were found to be homogenous among different Indian
populations as compared to the Chinese, European and Mexican-
American populations (Table 8).
Given the significant association of certain haplotypes, we
analyzed the pattern of haplotype distribution vis-a `-vis the
different clinical phenotypes of PCOS. Irrespective of the
association pattern, we observed two haplotype combinations:
while 21111/21221 was more prominent among the PCOS cases
with hirsutism, the other combination (11111/21221) showed a
relatively greater frequency among the cases with infertility,
obesity and elevated cholesterol levels, suggesting variable effect of
UCSNP-44 depending on its presence in homozygous/heterozy-
gous state. Overall, the results of our pioneering study among the
Indian women are concurrent to the earlier observations that
emphasize the role of CAPN10 UCSNP-44 in the manifestation of
PCOS. Nevertheless, further studies are warranted to replicate the
association patterns in larger cohorts of ethnically diverse
populations of India so as to reach unequivocal conclusion on
the role of CAPN10 polymorphisms in PCOS. Functional studies
based on the regulatory regions of this gene would be required
further to help gain more meaningful further insights on the
precise etiological role of CAPN10 towards PCOS phenotype.
Materials and Methods
Study design
A total of 549 women consisting of 250 PCOS cases (aged 14–
40 years) and 299 controls (aged 14–47 years) were enrolled for the
present study from July 2008 to April 2009. Patients were
recruited from the Gynecology clinic of the Osmania General
Hospital, Hyderabad as well as from an infertility clinic (Anu’s
Test Tube Baby Centre, Hyderabad) as per the Rotterdam
criteria, 2003 (The Rotterdam ESHRE/ASRM-sponsored PCOS
Consensus Workshop Group, 2004) [21] according to which any
Table 8. Minor allele frequencies of CAPN10 markers in different populations.
Genetic Marker China
a USA
a
Mexican Americ-
ans
a Finland
a Germany UK
c Spain
d India
i
a ii
b i
e ii
f ii
g iii
h
UCSNP-44 – – 0.06 – – 0.15 0.15 0.11 0.19 0.21 – 0.22
UCSNP-43 0.06 0.19 0.27 0.32 0.29 0.31 0.25 0.24 0.14 0.02 0.19 0.09
UCSNP-56 – – – – – 0.38 – – – – – 0.50
UCSNP-19 0.38 0.40 0.41 0.28 0.29 0.37 0.39 0.34 0.56 0.30 0.40 0.45
UCSNP-63 0.31 0.06 0.23 0.03 0.04 0.06 0.07 0.08 0.03 0.05 0.02 0.05
aHorikawa et al. (2000).
bVollmert et al. (2007).
cEvans et al. (2001).
dGonzalez et al. (2004).
eCassell et al. (2002).
fBodhini et al. (2010).
gAdak et al. (2010).
hPresent study.
doi:10.1371/journal.pone.0032192.t008
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inclusion: (i) presence of clinical and/or biochemical signs of
hyperandrogenism, (ii) infrequent periods with intermenstrual
interval of more than 35 days, and (iii) polycystic ovaries; an ovary
with the ultrasound appearance of more than 10 subcapsular
follicles (,10 mm in diameter) in the presence of prominent
ovarian stroma was considered polycystic. Patients with hyper-
prolactinemia, thyroid and adrenal diseases, 21-hydroxylase
deficiency, and androgen-secreting tumors were excluded. The
weight and height of the subjects were recorded. Hirsutism was
defined as a Ferriman-Gallwey score of more than 5 [22].
Hormonal assays that were recorded included serum levels of
gonadotrophic hormones {luteinizing hormone (LH) and follicle
stimulating hormone (FSH)}, thyroid stimulating hormone (TSH),
prolactin, testosterone (total), fasting insulin (FI) and random blood
sugar (RBS) levels. Normal controls with no history of treatment
for fertility, no evidence of clinical hyperandrogenism (hirsutism/
acne/alopecia), and with normal menstrual cycles every 25–32
days were recruited from the family planning center of the
Osmania hospital and from the general population.
Ethics Statement
Intravenous blood samples (,5 ml) were collected from both
the patients and controls after obtaining their informed written
consent. The study protocol was approved by the Indian Statistical
Institute Review Committee for Protection of Research Risks to
Humans.
DNA extraction, amplification and sequencing
DNA was extracted from the peripheral blood samples of the
patients and controls using the phenol-chloroform method [23].
We carried out PCR amplification and sequencing to screen the
CAPN10 polymorphisms using the forward and reverse primers.
Each PCR was optimized with respect to the concentration of
Mg2+ ions. The PCR-mix consisted of 106PCRBuffer, 10 mM
dNTP-mix, 1 mM of each primer, 1 U Taq-polymerase and 40 ng
template DNA in a reaction volume of 10 ml. Reactions were
carried out in an ABI GeneAmp9700 thermal cycler (Applied
Biosystems, Foster City, CA). Forward and reverse primers and
annealing temperature are given in Table 9.
Cycle Sequencing of PCR products were carried out with either
the forward or the reverse primers using the Big-Dye Terminator
ready reaction kit (Applied Biosystems, Foster City, CA). Extended
products were purified by ethanol precipitation and analyzed on
an ABI 3730 automated DNA Analyzer (Applied Biosystems,
Foster City, CA). No new data has been generated through our
sequencing work. Since only the known polymorphisms of
CAPN10 gene have been sequenced, the respective rsIDs are
provided in the tables.
Statistical Analysis
All the statistical analyses were performed with the help of SPSS
statistical software (version 19.0, IBM SPSS). Power of the study
was calculated using G*Power software (version 3.1). The Hardy-
Weinberg equilibrium was estimated by the x
2 test using Pypop
software. Haploview and THESIAS softwares were used to
estimate LD and generate haplotype frequencies. For all tests,
significance level was set as p,0.05
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